ENVB.US Enveric Biosciences Inc

Healthcare Biotechnology USA Stocks
1.51 USD
Close of Nov 14, 2026
1.17 13.25
Market cap
USD 6.78M
P/E
-
P/B
0.84x
ROE
-167.9%
Dividend yield
49.54%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ENVB.US undervalued?

Graham number

The Graham number of Enveric Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Enveric Biosciences Inc fundamental analysis

No fundamental analysis for Enveric Biosciences Inc yet.

Enveric Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Enveric Biosciences Inc

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to targe…

Full company profile